NCT01659151 2026-02-20Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic MelanomaH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Completed17 enrolled 11 charts
NCT04551521 2025-01-08CRAFT: The NCT-PMO-1602 Phase II TrialGerman Cancer Research CenterPhase 2 Completed72 enrolled
NCT01531361 2021-01-22Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF MutationsM.D. Anderson Cancer CenterPhase 1 Completed46 enrolled